Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

Breast Cancer Research and Treatment

Volumn 130, Issue 3, 2011, Pages 1029-1036

  Baek, Jong Min ^a   Jin, Quanri ^a   Ensor, Joe ^a   Boulbes, Delphine R ^a   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; HER2; Soluble CD44; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERMES ANTIGEN BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 82255162865     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1691-z     Document Type: Article

References (36)

1. M Al-Hajj MS Wicha A Benito-Hernandez SJ Morrison MF Clarke 2003 Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 3983 3988 12629218 10.1073/pnas.0530291100 1:CAS:528: DC%2BD3sXivFSqtbs%3D (Pubitemid 36418143)
2. I Stamenkovic A Aruffo M Amiot B Seed 1991 The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells EMBO J 10 343 348 1991450 1:CAS:528:DyaK3MXkvV2rsrk%3D (Pubitemid 21905484)
3. O Nagano H Saya 2004 Mechanism and biological significance of CD44 cleavage Cancer Sci 95 930 935 15596040 10.1111/j.1349-7006.2004.tb03179.x 1:CAS:528:DC%2BD2MXhtlOjsb8%3D (Pubitemid 40089583)
4. I Okamoto H Tsuiki LC Kenyon, et al. 2002 Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors Am J Pathol 160 441 447 11839564 10.1016/S0002-9440(10)64863-8 1:CAS:528:DC%2BD38XitVCksrg%3D (Pubitemid 34160321)
5. YJ Guo G Liu X Wang, et al. 1994 Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer Cancer Res 54 422 426 7506122 1:STN:280:DyaK2c7gtFKitw%3D%3D (Pubitemid 24053180)
6. C Lackner R Moser T Bauernhofer, et al. 1998 Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis Breast Cancer Res Treat 47 29 40 9493973 10.1023/A:1005913514376 1:STN:280: DyaK1c7lt12qsA%3D%3D (Pubitemid 28048148)
7. S Molica G Vitelli D Levato D Giannarelli GM Gandolfo 2001 Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression Cancer 92 713 719 11550139 10.1002/1097-0142(20010815)92:4<713::AID-CNCR1374>3.0. CO;2-O 1:CAS:528:DC%2BD3MXmvFKns7s%3D (Pubitemid 32783054)
8. N Niitsu K Iijima 2002 High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma Leuk Res 26 241 248 11792412 10.1016/S0145-2126(01)00122-9 1:CAS:528:DC%2BD38XktVKrsA%3D%3D (Pubitemid 34037020)
9. N Guriec L Marcellin B Gairard, et al. 1996 CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma Clin Exp Metastasis 14 434 439 8871537 10.1007/BF00128959 1:CAS:528: DyaK28XntVGjsLg%3D (Pubitemid 26365120)
10. MS Lockhart C Waldner C Mongini, et al. 1999 Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma Oncol Rep 6 1129 1133 10425314 1:STN:280:DyaK1Mzls1SmtA%3D%3D
11. M Sanchez Lockhart SE Hajos FM Basilio C Mongini E Alvarez 2001 Splice variant expression of CD44 in patients with breast and ovarian cancer Oncol Rep 8 145 151 11115587 1:STN:280:DC%2BD3M7ivFyjtw%3D%3D (Pubitemid 33758218)
12. S Mayer A zur Hausen DO Watermann, et al. 2008 Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients J Cancer Res Clin Oncol 134 1229 1235 18438684 10.1007/s00432-008-0397-z 1:CAS:528:DC%2BD1cXht1anu73M
13. SM Sheen-Chen WJ Chen HL Eng CC Sheen FF Chou YF Cheng 1999 Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer Cancer Invest 17 581 585 10592765 10.3109/07357909909032843 1:STN:280: DC%2BD3c%2FmtVemsg%3D%3D
14. Z Amirghofran SA Jalali SV Hosseini M Vasei B Sabayan A Ghaderi 2008 Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis J Gastrointest Cancer 39 73 78 19333790 10.1007/s12029-009-9062-2 1:CAS:528:DC%2BD1MXnsVajsLs%3D
15. AC Woodman M Sugiyama K Yoshida, et al. 1996 Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms Am J Pathol 149 1519 1530 8909242 1:CAS:528:DyaK28XntlGktLw%3D (Pubitemid 26363959)
16. JM Bhatavdekar DD Patel NG Shah, et al. 2000 Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis Ann Surg Oncol 7 305 311 10819372 10.1007/s10434-000-0305-5 1:STN:280:DC%2BD3c3nslGhsQ%3D%3D (Pubitemid 30318320)
17. N Yamane S Tsujitani M Makino M Maeta N Kaibara 1999 Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer Oncology 56 232 238 10202279 10.1159/000011970 1:CAS:528:DyaK1MXisFGhtr8%3D (Pubitemid 29161293)
18. LL Kokko S Hurme SM Maula, et al. 2011 Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma Oral Oncol 47 6 510 516 21514878 10.1016/j.oraloncology.2011.03.026 1:CAS:528:DC%2BC3MXnt1KrtLs%3D
19. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS (2001) Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7(3):171-177 (Pubitemid 33716851)
20. H Korkaya A Paulson F Iovino MS Wicha 2008 HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion Oncogene 27 6120 6130 18591932 10.1038/onc.2008.207 1:CAS:528:DC%2BD1cXht1Cms7rJ
21. X Li MT Lewis J Huang, et al. 2008 Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Inst 100 672 679 18445819 10.1093/jnci/djn123 1:CAS:528:DC%2BD1cXlslymtbg%3D
22. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 16932852 10.1007/s10549-006-9242-8 (Pubitemid 44631925)
23. U Gunthert M Hofmann W Rudy, et al. 1991 A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells Cell 65 13 24 1707342 10.1016/0092-8674(91)90403-L 1:STN:280:DyaK3M7ptFGmsA%3D%3D (Pubitemid 121001209)
24. S Seiter R Arch S Reber, et al. 1993 Prevention of tumor metastasis formation by anti-variant CD44 J Exp Med 177 443 455 8426113 10.1084/jem.177.2.443 1:CAS:528:DyaK3sXnvV2rsg%3D%3D (Pubitemid 23117094)
25. D Masson MG Denis M Denis, et al. 1999 Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer Br J Cancer 80 1995 2000 10471052 10.1038/sj.bjc.6690633 1:CAS:528:DyaK1MXlvVais70%3D (Pubitemid 29391287)
26. R Kopp S Classen H Wolf P Gholam K Possinger W Wilmanns 2001 Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer Anticancer Res 21 2995 3000 11712800 1:CAS:528:DC%2BD3MXovVWgt7w%3D (Pubitemid 33051165)
27. J Zhou PS Nagarkatti Y Zhong K Creek J Zhang M Nagarkatti 2010 Unique SNP in CD44 intron 1 and its role in breast cancer development Anticancer Res 30 1263 1272 20530438
28. S Weg-Remers U Hildebrandt G Feifel C Moser M Zeitz A Stallmach 1998 Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6 Am J Gastroenterol 93 790 794 9625129 10.1111/j.1572-0241.1998.226-a.x 1:CAS:528:DyaK1cXmt1Grsb4%3D (Pubitemid 29063923)
29. B Zalewski 2004 Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features World J Gastroenterol 10 583 585 14966921 1:CAS:528:DC%2BD2cXislalurk%3D (Pubitemid 38325319)
30. M Gotte GW Yip 2006 Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective Cancer Res 66 10233 10237 17079438 10.1158/0008-5472.CAN- 06-1464 (Pubitemid 44799736)
31. SM Chang RD Xing FM Zhang YQ Duan 2009 Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy Oral Dis 15 570 572 19563418 10.1111/j.1601-0825.2009.01591.x 1:STN:280:DC%2BD1Mnos12rtQ%3D%3D
32. HJ Kim MJ Kim SH Ahn, et al. 2011 Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status Breast 20 78 85 20810282 10.1016/j.breast.2010.08.001
33. H Saito S Tsujitani K Katano M Ikeguchi M Maeta N Kaibara 1998 Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma Cancer 83 1094 1101 9740073 10.1002/(SICI)1097-0142(19980915) 83:6<1094::AID-CNCR7>3.0.CO;2-8 1:STN:280:DyaK1cvhtVOruw%3D%3D (Pubitemid 28419061)
34. P Klingbeil R Natrajan G Everitt, et al. 2010 CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification Breast Cancer Res Treat 120 95 109 19350388 10.1007/s10549-009-0380-7 1:CAS:528:DC%2BC3cXntlarsQ%3D%3D
35. NG Shah TI Trivedi HH Vora, et al. 2010 CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study Tumori 96 971 977 21388061 1:CAS:528:DC%2BC3MXhtFCrtrrO
36. HS Berner Z Suo B Risberg K Villman MG Karlsson JM Nesland 2003 Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas Histopathology 42 546 554 12786890 10.1046/j.1365-2559.2003. 01622.x 1:STN:280:DC%2BD3s3mtFOmtA%3D%3D (Pubitemid 36688148)